A company with a mission to reduce the cost, time and risk of bringing innovative medicines to patients
HUYABIO International was founded to identify promising biopharmaceutical innovation from China and accelerate its development for patients globally.
Its model focuses on in-licensing drug candidates that have already generated clinical or pre-clinical data, with the aim of reducing the time, cost and risk traditionally associated with bringing new medicines to international markets.
Spearheaded by HUYABIO Founder, CEO and Executive Chair Lady Mireille Gillings, PhD, who saw the potential for innovation in China more than 20 years ago, HUYABIO has spent over two decades building its presence and networks in the country.
HUYABIO is now a leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China, with first-mover advantage as the industry increasingly looks to the Chinese market for opportunities to license innovative assets.